Tue, Nov 26, 2024 1:55 PM
Sagility India Consolidated September 2024 Net Sales at Rs 1,325.05 crore
A Flip by Shubhangi Gupta
C2C Advanced's shares commanded a GMP of Rs 245 as of November 24, translating to a premium of over 100%, although listing gains are capped at 90%. However, the premium has since plunged to Rs 100 as of November 26, reflecting a potential listing gain of approximately 45%, according to the data available on Investorgain. This marks a decline of nearly 59.18% in just two days.
Open Flip
AstraZeneca Pharma India Ltd has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute the cancer treatment drug Olaparib, branded as Lynparza, in India. The approval allows the company to import the drug in film-coated tablet form in dosages of 100 mg and 150 mg for sale and distribution in the country.
Open Flip
Reported Standalone quarterly numbers for PG Foils are: Net Sales at Rs 100.27 crore in September 2024 up 66.14% from Rs. 60.36 crore in September 2023. Quarterly Net Profit at Rs. 6.86 crore in September 2024 up 1495.93% from Rs. 0.43 crore in September 2023. EBITDA stands at Rs. 10.65 crore in September 2024 up 201.7% from Rs. 3.53 crore in September 2023.
Open Flip
